TKPYY : Summary for TAKEDA PHARMA - Yahoo Finance

U.S. Markets open in 1 hr 12 mins

Takeda Pharmaceutical Company Limited (TKPYY)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
20.94+0.27 (+1.31%)
At close: 3:57PM EST
People also watch
ALPMYESALYDSNKYTKPHFSVNDY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close20.67
Open20.90
Bid0.00 x
Ask0.00 x
Day's Range20.46 - 20.96
52 Week Range19.96 - 25.40
Volume139,480
Avg. Volume87,816
Market Cap32.24B
Beta0.31
PE Ratio (TTM)24.81
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.78 (3.80%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals4 days ago

    Ariad played hardball to boost Takeda buyout price, federal filings show

    Takeda’s $5.2 billion acquisition of Ariad Pharmaceuticals on Jan. 9 valued the Cambridge cancer drug firm at $24 per share, a 75 percent premium over its previous closing stock price. A federal filing by Ariad (ARIA) on Thursday includes a lengthy play-by-play of the negotiations, beginning with a phone call on Dec. 2 between Ariad CEO Paris Panayiotopoulos and Takeda CEO Christophe Weber. During the call, Panayiotopoulos told Weber that if Takeda was interested in making a “broader” deal, it should do so in writing, according to the filing.

  • Financial Times6 days ago

    [$$] US biotech Ovid to develop Takeda epilepsy drug in outsourcing tie-up

    Takeda, Japan's largest drugmaker, has outsourced the development of a drug for rare forms of childhood epilepsy to a US biotech company in an unusual deal that underscores the growing importance of smaller ...

  • Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short
    Zacks13 days ago

    Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short

    Several licensing deals and agreements were announced this week including the $5.2 billion ARIAD (ARIA) acquisition.